Hi there,
Our investment research analysts are going to be releasing their next investment idea tomorrow morning, around 10:00 AM Eastern time.
It will be first sent to subscribers that sign up to receive American Market News via SMS, then later in the morning to people who subscribe to our email newsletter or read our content on our website.
Don't miss out on your opportunity to be among the first to see our next stock idea. Our last idea was quite popular with our subscribers.
This is a free service from American Market News. If you want to take advantage of this unique research opportunity, just click the link below to be added to our priority distribution list.
Get Research Alerts from American Market News
Jessica Mitacek
Managing Editor
American Market News
Figma's Anthropic Integration Could Flip the SaaSpocalypse Script
Author: Jeffrey Neal Johnson. Article Published: 2/19/2026.
Key Points
- Figma reported accelerating fourth-quarter revenue growth that exceeded analyst estimates on both the top and bottom lines.
- A new strategic partnership with Anthropic allows developers to instantly turn generated code into editable designs directly on the platform.
- Large enterprise customers are increasing their spending and expanding usage across the platform rather than cutting their software budgets.
- Special Report: [Sponsorship-Ad-6-Format3]
Figma (NYSE: FIG) delivered a fiscal fourth-quarter performance that not only beat expectations but also challenged a prevailing market fear. For months, a narrative dubbed the "SaaSpocalypse" has weighed on software stocks: investors worried that generative artificial intelligence (AI) would displace traditional Software-as-a-Service (SaaS) business models. The theory was simple but alarming: if AI can design interfaces and write code, companies will need fewer human workers and, consequently, fewer software subscriptions.
Figma's latest results suggest the opposite. The company reported fourth-quarter revenue of $303.8 million, an accelerated year-over-year growth rate of 40%. This performance exceeded analyst estimates on both the top and bottom lines and triggered a sharp rally in after-hours trading. Before the release, the stock had struggled in 2026, trading near $24 per share, well below its IPO price. The report signals a potential reversal in sentiment, driven by data showing AI is not replacing Figma but becoming a core engine for its expansion.
From Design Tool to Developer Ecosystem
Buy this stock tomorrow? (Ad)
Not a Single "Mag 7" on This Legendary Investors List
A renowned former hedge fund manager – friends to some of the biggest investors in the world – just released a new list of his favorite AI stocks... and not a single Magnificent 7 name made the cut. Instead, an AI stock you've likely never heard of just flagged as "near-perfect" in his new investing scoring system.
The most significant update for long-term investors is not on the balance sheet but in the product roadmap. Figma announced a strategic integration with Anthropic, the creators of the Claude AI model. The new feature, dubbed Code to Canvas, allows developers to generate user interfaces using Claude Code in a terminal and instantly import them into Figma as fully editable designs.
This development directly counters the bearish argument that AI coding agents will render design software obsolete. Rather than bypassing Figma, AI agents are using it as their visual interface. Developers can rapidly generate application structures via text prompts and then move them into Figma for refinement. That turns AI from a competitor into a workflow accelerator, keeping Figma as the essential bridge between code and visual design.
At the same time, Figma is expanding its total addressable market beyond professional designers. Management highlighted the explosive growth of Figma Make, a rapid prototyping tool: weekly active users of the product increased by more than 70% from the prior quarter.
Key Product Growth Stats:
- Non-Designer Adoption: Nearly 60% of files created in Figma Make were generated by non-designers such as product managers and developers.
- Cross-Pollination: Over 80% of Figma Make users also used the core Figma Design product, underscoring the suite's stickiness.
These figures show the platform is becoming an organizational necessity for entire product teams rather than a niche tool for graphic artists. By integrating with developer workflows and reinforcing ties with platforms like GitHub, Figma is embedding itself deeper into the software development lifecycle.
Why Customers Are Staying Put
While the product story is compelling, the financial fundamentals provide the concrete evidence investors require. Figma is showing accelerating growth at a time when many software peers are slowing. The 40% revenue growth in the fourth quarter represents a meaningful uptick, validating demand for collaborative design tools.
Arguably the most impressive metric in the report was Net Dollar Retention (NDR). An NDR above 100% means existing customers are spending more over time.
- NDR Performance: The rate rose to 136%, up 5 percentage points from the previous quarter.
- Customer Growth: The company now serves 1,405 customers generating more than $100,000 in annual recurring revenue (ARR), a 46% increase year-over-year.
- International Reach: Revenue from markets outside the U.S. grew 45%, now representing 54% of total revenue.
These numbers indicate large enterprise clients are not cutting costs or churning; they are expanding their usage of the platform. That contradicts fears that macroeconomic tightening is forcing businesses to slash software budgets.
Looking ahead, management provided bullish guidance for fiscal year 2026, projecting revenue between $1.366 billion and $1.374 billion, implying continued strong growth of roughly 30%. A major monetization catalyst is scheduled for March 2026: Figma will begin implementing limits on AI credits and introducing pay-as-you-go plans for heavy users. That moves the company from a purely seat-based subscription model toward a hybrid model that includes consumption-based revenue. As AI adoption scales, the structure offers meaningful upside potential for revenue per user.
Price vs. Value: Is the Sell-Off Over?
Despite the strong fundamentals, Figma's stock price has been volatile. Trading near $24 before the earnings release, the stock sits well below its initial public offering (IPO) price of $33 and far off its post-IPO peak of roughly $143. That price dislocation frames the current opportunity for investors.
The decline was driven largely by two factors: a broad sector sell-off tied to AI fears and heavy insider selling after the IPO lock-up period expired in January 2026. While insider selling can alarm retail investors, it is a routine liquidity event for newly public companies. Executives selling shares are often diversifying their holdings, which does not necessarily signal a lack of confidence—especially when balanced against confirmed 40% growth.
Moreover, Figma is not growing at all costs. The company reported a healthy non-GAAP operating margin of 14% and generated $38.5 million in adjusted free cash flow.
Balance Sheet Highlights:
- Cash Position: The company ended the year with $1.7 billion in cash, cash equivalents, and marketable securities.
- Debt: The company maintains a healthy balance sheet with no material debt.
This mix of high growth, profitability, and a strong balance sheet suggests a sustainable business model less reliant on external capital than many high-growth peers. At current valuation levels, the market appears to have priced in worst-case AI scenarios, potentially overlooking the upside from the Anthropic partnership and upcoming monetization changes.
A Beat and Raise Validating the AI Strategy
Figma's fourth quarter was a classic beat-and-raise that validates management's strategy of embracing the AI revolution rather than fighting it. By integrating deeply with developer workflows through partnerships like Anthropic, the company is building a defensive moat against competitors like Adobe (NASDAQ: ADBE) while going on the offensive to capture non-designer users.
The combination of accelerating revenue, a sticky enterprise customer base with 136% retention, and new consumption-based revenue streams positions the company well for 2026. Figma is evolving from a simple design tool into a central operating system for product development, making it a compelling growth story for investors willing to look past short-term volatility.
After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound
Author: Leo Miller. Article Published: 2/27/2026.
Key Points
- Tempus AI’s post-IPO volatility has reset expectations, but Q4 results showed strong organic growth alongside acquisition-fueled gains.
- Management’s 2026 outlook points to a potential full-year adjusted EBITDA inflection, a key milestone for the story.
- The company’s large multimodal dataset and entrenched testing channels may make disruption harder, even as analyst targets trend lower.
- Special Report: [Sponsorship-Ad-6-Format3]
Since going public in mid-2024, shares of healthcare and life sciences services company Tempus AI (NASDAQ: TEM) have taken a wild ride. The firm's initial public offering price was $37. The stock climbed above $85 by February 2025, fell to around $50 two months later, and then rebounded above $100 in October. Around that rebound, MarketBeat cautioned investors, noting multiple overvaluation signals. The stock now trades near $54 per share, down almost 50% from its all-time high.
Tempus just reported its latest financial results, and the stock fell about 7% on the news. Still, with shares down so sharply, this is a company worth revisiting.
TEM Tops Estimates, Projects Full-Year EBITDA Inflection in 2026
Buy this stock tomorrow? (Ad)
Not a Single "Mag 7" on This Legendary Investors List
A renowned former hedge fund manager – friends to some of the biggest investors in the world – just released a new list of his favorite AI stocks... and not a single Magnificent 7 name made the cut. Instead, an AI stock you've likely never heard of just flagged as "near-perfect" in his new investing scoring system.
In Q4 2025, Tempus grew revenue 83% to $367 million, beating estimates. Much of that growth reflected acquisitions, which inflated the topline, but organic revenue rose an impressive 33.5%. The company posted an adjusted loss per share of $0.04, slightly better than the $0.05 loss analysts had expected.
Testing volume growth in the company's oncology and hereditary business lines came in at 29% and 23%, respectively. Maintaining solid growth here is key: more tests not only generate diagnostic revenue but also feed the company's data and applications business.
Tempus sells the data generated from its tests to pharmaceutical companies, which use it to improve clinical trial success rates. Data and applications revenue increased 25%, a slight deceleration from 26% in the prior quarter. The company's net retention rate was 126% for the full year, meaning existing customers from 2024 increased their spending by 26% in 2025.
Profitability is also improving. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) totaled $12.9 million, up from an adjusted EBITDA loss of $7.8 million in Q4 2024.
Looking ahead, Tempus expects revenue growth of roughly 25% in 2026 and forecasts adjusted EBITDA of $65 million. That would put adjusted EBITDA in positive territory for a full year for the first time in the company's history.
TEM's Huge 450-Petabyte Dataset: An AI-Disruption Shield
The threat from artificial intelligence disrupting Tempus appears limited. Tempus has amassed roughly 450 petabytes of multimodal data that it can use to train its own models — a substantial competitive asset.
Data storage company Pure Storage (NYSE: PSTG), which will begin trading under the name Everpure on March 5, helps put that figure in context. They estimate that with 3.6 billion exams conducted annually, the healthcare sector generates around 450 petabytes of imaging data per year. In other words, Tempus's dataset is similar in size to all the imaging the healthcare system produces annually — a staggering statistic.
Tempus's head start in accumulating this data is large and growing, and it would be difficult for new competitors to replicate quickly. The dataset has more than tripled since 2022, when it was under 150 petabytes. Much of this data comes from Tempus's diagnostics business, where it performs oncology and hereditary testing. The company says more than 8,500 oncologists and thousands of other physicians regularly order tests, giving it a strong foothold.
Building a comparable training dataset would require performing clinical testing — something major AI firms do not currently do and likely would not prioritize. For many AI labs, attacking software-as-a-service business models is a more natural path to commercialization; their models have already been trained on coding and other public datasets and typically don't need to replicate clinical-scale data collection to develop competing products.
Tempus is developing its own foundational model and has submitted it to pharma giant AstraZeneca (NASDAQ: AZN) for review. Monetization of that model remains nascent but represents a potential new revenue stream.
Even After Lowering Targets, Analysts Eye Solid Gains Ahead
The MarketBeat consensus price target on Tempus sits near $79, implying roughly 40% upside.
That said, many analysts have not updated their targets recently.
Among targets issued or updated after Tempus's earnings release, the average is moderately lower at about $71, which still implies upside of more than 30%.
Overall, Tempus is seeing strong demand for its offerings, and existing customers are increasing their spend — a sign the company is delivering value and creating upsell opportunities.
Given those factors, Tempus shares appear to have a meaningful opportunity to rebound.
This email communication is a paid advertisement provided by American Market News, a third-party advertiser of MarketBeat. Why did I get this email content?.
If you have questions about your subscription, please don't hesitate to contact our South Dakota based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
Copyright 2006-2026 MarketBeat Media, LLC. All rights protected.
345 N Reid Place, Sixth Floor, Sioux Falls, South Dakota 57103. U.S.A..
No comments:
Post a Comment